BlackRock
CMPX icon

BlackRock’s Compass Therapeutics CMPX Stock Holding History

BlackRock’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$50.3M Buy
9,506,080
+117,456
+1% +$678K ﹤0.01% 2491
2025
Q4 		$50.4M Buy
9,388,624
+2,017,877
+27% +$9.32M ﹤0.01% 2509
2025
Q3 		$25.8M Buy
7,370,747
+957,614
+15% +$3.02M ﹤0.01% 2930
2025
Q2 		$16.7M Sell
6,413,133
-695,957
-10% -$1.44M ﹤0.01% 3139
2025
Q1 		$13.5M Buy
7,109,090
+221,475
+3% +$589K ﹤0.01% 3158
2024
Q4 		$9.99M Buy
6,887,615
+67,163
+1% +$112K ﹤0.01% 3430
2024
Q3 		$12.5M Buy
6,820,452
+206,815
+3% +$258K ﹤0.01% 3288
2024
Q2 		$6.61M Buy
6,613,637
+581,171
+10% +$849K ﹤0.01% 3580
2024
Q1 		$11.9M Sell
6,032,466
-189,843
-3% -$328K ﹤0.01% 3259
2023
Q4 		$9.71M Buy
6,222,309
+248,574
+4% +$430K ﹤0.01% 3412
2023
Q3 		$11.8M Sell
5,973,735
-58,557
-1% -$145K ﹤0.01% 3241
2023
Q2 		$19.2M Buy
6,032,292
+4,491,397
+291% +$14.1M ﹤0.01% 3060
2023
Q1 		$5.04M Buy
1,540,895
+303,114
+24% +$1.19M ﹤0.01% 3636
2022
Q4 		$6.23M Buy
1,237,781
+365,284
+42% +$1.46M ﹤0.01% 3627
2022
Q3 		$1.99M Buy
872,497
+709,071
+434% +$1.96M ﹤0.01% 4200
2022
Q2 		$433K Buy
+163,426
New +$355K ﹤0.01% 4812

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock's CMPX Position: Q1 2026 in Review

BlackRock increased its Compass Therapeutics (CMPX) stake by 1.3% in Q1 2026, buying an estimated $678K and bringing the position to 9,506,080 shares worth $50.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2491.

BlackRock first reported a position in CMPX in Q2 2022 and has held it in 16 quarters since. The position peaked at $50.4M in Q4 2025. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • BlackRock held 9,506,080 shares of Compass Therapeutics worth $50.3M as of Q1 2026.
  • BlackRock bought 117,456 Compass Therapeutics shares in Q1 2026, an estimated $678K.
  • Compass Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #2491 holding.
  • BlackRock first reported a position in Compass Therapeutics in Q2 2022 and has held it in 16 quarters since.
  • BlackRock's Compass Therapeutics position peaked at $50.4M in Q4 2025.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.